Vistagen Therapeutics, Inc.

VTGN · Nasdaq · SIC 2834: Pharmaceutical Preparations
386
SEC Filings

Business Summary

VistaGen Therapeutics is a late clinical-stage biopharmaceutical company developing non-systemic intranasal pherine product candidates that activate nose-to-brain neurocircuits without systemic absorption. Its pipeline includes five clinical-stage candidates: fasedienol (Phase 3, social anxiety disorder), itruvone (Phase 2A, major depressive disorder), PH80 (Phase 2A, vasomotor symptoms and premenstrual dysphoric disorder), PH15 (Phase 2A, mental fatigue), and PH284 (Phase 2A, cancer cachexia). Fasedienol is the lead candidate in the registration-directed PALISADE Program.

Next Earnings

Q2 FY2026 — expected 2026-09-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionVTGNdiscussed_in_filing Cybersecurity
topic_mentionVTGNdiscussed_in_filing Trusted Computing
topic_mentionVTGNdiscussed_in_filing Blockchain & Crypto
topic_mentionVTGNdiscussed_in_filing Regulation
topic_mentionVTGNdiscussed_in_filing Healthcare & Bio
topic_mentionVTGNdiscussed_in_filing Sovereign & Government
topic_mentionVTGNdiscussed_in_filing Cybersecurity
topic_mentionVTGNdiscussed_in_filing Trusted Computing
topic_mentionVTGNdiscussed_in_filing Blockchain & Crypto
topic_mentionVTGNdiscussed_in_filing Regulation
topic_mentionVTGNdiscussed_in_filing Healthcare & Bio
topic_mentionVTGNdiscussed_in_filing Sovereign & Government
topic_mentionVTGNdiscussed_in_filing Cybersecurity
topic_mentionVTGNdiscussed_in_filing Trusted Computing
topic_mentionVTGNdiscussed_in_filing Blockchain & Crypto
topic_mentionVTGNdiscussed_in_filing Regulation
topic_mentionVTGNdiscussed_in_filing Healthcare & Bio
topic_mentionVTGNdiscussed_in_filing Sovereign & Government
topic_mentionVTGNdiscussed_in_filing Cybersecurity
topic_mentionVTGNdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-06-172025-03-310001411685-25-000041EDGAR86K words
2024-06-112024-03-310001411685-24-000022EDGAR—
2023-06-282023-03-310001437749-23-018793EDGAR—
2022-06-232022-03-310001851734-22-000349EDGAR—
2021-06-292021-03-310001654954-21-007380EDGAR—
2020-06-292020-03-310001654954-20-007107EDGAR—
2019-06-252019-03-310001654954-19-007632EDGAR—
2018-06-262018-03-310001654954-18-006990EDGAR—
2017-06-292017-03-310001654954-17-005976EDGAR—
2016-06-242016-03-310001415889-16-006331EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-122025-12-310001628280-26-007718EDGAR60K words
2025-11-132025-09-300001628280-25-052079EDGAR—
2025-08-072025-06-300001411685-25-000064EDGAR—
2025-02-132024-12-310001411685-25-000019EDGAR—
2024-11-072024-09-300001411685-24-000048EDGAR—
2024-08-132024-06-300001411685-24-000037EDGAR—
2024-02-132023-12-310001437749-24-003916EDGAR—
2023-11-092023-09-300001437749-23-031293EDGAR—
2023-08-102023-06-300001437749-23-023127EDGAR—
2023-02-072022-12-310001851734-23-000035EDGAR—
2022-11-102022-09-300001851734-22-000662EDGAR—
2022-08-112022-06-300001851734-22-000432EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001628280-26-023176EDGAR1K words
2026-03-180001628280-26-019455EDGAR—
2026-03-160001628280-26-018163EDGAR—
2026-03-110001628280-26-016652EDGAR—
2026-02-200001628280-26-010035EDGAR—
2026-02-120001628280-26-007715EDGAR—
2026-02-060001628280-26-006078EDGAR—
2026-01-090001628280-26-001690EDGAR—
2025-12-220001628280-25-058594EDGAR—
2025-12-030001628280-25-055083EDGAR—

386 total filings indexed. 354 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

social-anxiety-disorder major-depressive-disorder vasomotor-symptoms-due-to-menopause premenstrual-dysphoric-disorder mental-fatigue cancer-cachexia neuroscience-/-neuropsychiatry subjective-units-of-distress-scale-(suds) clinical-global-impressions-improvement-(cgi-i) patients-global-impression-of-change-(pgi-c)

Company Identity

CIK0001411685
TickerVTGN
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedNV

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: cfa578f5b3abc39a1fe3d2bf3a0953c5b8921b9019ffd1ca99dd96d7da8221bd
parent: 99d7bc995160ccf9b58d7a64f06696ca83e94df169099ab07740f695470ac9d8
content hash: 006beaef2a798bf337415ce2017463856194a62b06a6cf2b67c69a5edb43d98b
signed: 2026-04-13T04:48:09.338Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf